Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery ROCHESTER, N.Y. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex , Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating